Publication | Closed Access

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Hematological MalignancyMedicineImmunologyHematologyPharmacotherapyLow-dose DexamethasoneOncologyRefractory Multiple MyelomaMyeloid Neoplasia